

A year in review: thirteen 2023 peer-reviewed journal articles featuring Fortrea oncologists.

Fortrea is proud to support our sponsors with a team of over 60 oncologists committed to navigating the complexities of oncology clinical research and maximizing the impact of their product to the current global therapeutic landscape. With support spanning translational research and early phase development through product launch and post-marketing studies, our team members help guide clinical development planning, establish target product profiles, perform feasibility and risk assessment and provide program-level medical oversight. This collaborative approach can result in co-authorship of peer-reviewed journal articles based on projects we've supported. They also have contributed to industry knowledge via articles about their own collaborative and academic work.



In 2023, Fortrea oncologists published 13 peer-reviewed articles. Just a few of the most interesting include:

“Quantifying the Impact of the COVID-19 Pandemic on Clinical Trial Enrollment Screening Rates Over Time in 37 Countries”

COVID-19 made a huge impact on all aspects of human activity, including biomedical research. Fortrea is among the world's leading CROs and intrinsically involved in the planning, set up, and execution of clinical trials globally. In this article, we analyzed the impact of the pandemic on the trial screening rates in 37 countries. Read the article here: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071259/>

“Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer”

Antibody-drug conjugates (ADCs) have emerged as one of the most exciting advances in cancer therapeutics in the past decade, and Fortrea has been involved in the execution of clinical trials for many such molecules. In this manuscript, we highlight the growing role of ADCs in non-small cell lung cancer. Read the article here: <https://www.sciencedirect.com/science/article/pii/S2468294223000345>

“CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond”

Cell and gene therapy, and in particular CAR-T cell therapy, has shown remarkable results in CD19-positive haematological cancers. In this paper, we review the recent progress made in testing CAR-T cell therapy to target B-cell maturation antigen-expressing cells in multiple myeloma. Read the article here: <https://www.mdpi.com/2076-393X/11/11/1721>

Check out the full list of our 2023 peer-reviewed oncology publications!

Number	Authors, Title, Journal
1	Filho P, Albuquerque C, Pilon M, Debiasi M. Immune checkpoint inhibitors in breast cancer: a narrative review. <i>Oncology and Therapy</i> . https://pubmed.ncbi.nlm.nih.gov/36917399/
2	McDonald K, Seltzer E, Lu M, Gaisenband S, Fletcher C, McLeroth P, Saini K. Quantifying the Impact of the COVID-19 Pandemic on Clinical Trial Enrollment Screening Rates Over Time in 37 Countries. <i>Trials</i> . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071259/
3	Salifu I, Singh N, Berraondo M, Remon J, Ramkissoon S, Vidal L, Chico I, Saini K. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> . https://www.sciencedirect.com/science/article/pii/S2468294223000345
4	Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierio PA, Aerts JGJV, Berardi R. Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicenter cohort study. <i>Journal of the National Cancer Institute</i> . https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djad061/7115841
5	Severson E, Achyut B.R., Nesline M, Pabla S, Previs R, Kannan G, Chenn A, Zhang S, Klein R, Conroy J, Sausen M, Sathyan P, Saini K, Ghosh A, Jensen T, Reddy P, Ramkissoon S. RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers. <i>The Journal of Molecular Diagnostics</i> . https://www.sciencedirect.com/science/article/pii/S1525157823000995
6	Czajka-Francuz P, Prendes M, Mankan A, Quintana Á, Pabla S, Ramkissoon S, Jensen T, Peiró S, Severson E, Achyut B, Vidal L, Poelman M and Saini K. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. <i>Frontiers in Oncology</i> . https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1200646/full
7	Mankan A, Czajka-Francuz P, Prendes M, Ramanan S, Koziej M, Vidal L, Saini K. Intracellular DNA sensing by neutrophils and amplification of the innate immune response. <i>Frontiers in Immunology</i> . https://www.frontiersin.org/articles/10.3389/fimmu.2023.1208137/full
8	Bodriagova O, Previs R, Gaba L, Shankar A, Vidal L, Saini K. Recent Advances in Gynecological Malignancies: Focus on ASCO 2023. <i>Oncology and Therapy</i> . https://rdcu.be/dmgOx
9	Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, Lo Russo G, Galli G, Proto C, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R. Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study. <i>Oncologist</i> . https://doi.org/10.1093/oncolo/oyad273

Number	Authors, Title, Journal
10	Dlamini Z, Molefi T, Khanyile R, Mkhabele M, Damane B, Kokoua A, Bida M, Saini K, Chauke-Malinga N, Luvhengo T, Hull R. From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa. <i>Oncology and Therapy</i> . https://link.springer.com/article/10.1007/s40487-023-00248-1
11	Ko H, Previs R, Strickland K, Caveney B, Chiruzzi C, Eisenberg M, Severson E, Ramkissoon S, Saini K. Is HER2-low a new clinical entity or merely a biomarker for an antibody drug conjugate? <i>Oncology and Therapy</i> . https://link.springer.com/article/10.1007/s40487-023-00249-0
12	Mishra A, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, Prasad C, Singh A, Bhat A, Macha M, Benali M, Saini K, Previs R, Saini D, Saha D, Dutta P, Bhatnagar A, Darwal M, Shankar A, Singh M. CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond. <i>Vaccines</i> . https://www.mdpi.com/2076-393X/11/11/1721
13	Cantini L, Trapani D, Guidi L, Bielo L, Scafetta R, Koziej M, Vidal L, Saini K, Curigliano G. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer. <i>Cancer Treatment Reviews</i> . https://www.cancertreatmentreviews.com/article/S0305-7372(23)00162-7/fulltext

Fortrea
Together, exceptional is possible

 **LEARN MORE** at fortrea.com